Identification of the best-suited donor for generating virus-specific T cells

Szabolcs Tasnády, Éva Karászi, Attila Szederjesi, György Bihari, Zsófia Juhász, Apor Hardi, Gergely Kriván, Krisztián Kállay, Péter Reményi, János Sinkó, Gábor Mikala, Marienn Réti, Tamás Masszi

Research output: Contribution to journalArticle

Abstract

Background and objectives: Administration of virus-specific T cells (VSTs) is a viable antiviral treatment strategy after allogeneic HSCT, even if conventional therapies fail. Third-party donors are often chosen for the generation of the VST product. The eligibility of the donor has to be tested in a rigorous donor screening procedure, since the isolation technology only targets pre-existing VSTs. Materials and methods: In a period of 3 years, we performed 32 VST treatments for 28 patients. Targeting four different viruses, 284 healthy individuals underwent 417 donor screening procedures. VSTs were counted by flow cytometry detecting interferon-gamma (IFN-γ) producing T cells. Generation of the VSTs was performed from leukapheresis products in a fully automated and closed system using magnetic cell separation. Results: The mean circulating VST frequencies ranged from 0·006% to 0·328%. The average yield of viable VSTs in the product was 1·83·106 cells, while the average VST dose calculated for the patient's body weight was 4·63·104/kg. The mean purity – percentage of VSTs within the T cells – of all T-cell products was 62·9%. Correlation was identified between the frequency of the VSTs in the peripheral blood of the donor and the VST numbers of the end product; the strongest correlation was seen for CMV. Conclusion: This paper focuses on the T-cell donors, highlighting some key points on the donor selection process. Based on the findings in connection with the CMV therapies, peripheral VST seems to be the best predictor of the VST content of the final product administered to the patient.

Original languageEnglish
JournalVox sanguinis
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Donor Selection
Tissue Donors
Viruses
T-Lymphocytes
Leukapheresis
Cell Separation
Therapeutics
Blood Donors
Interferon-gamma
Antiviral Agents
Flow Cytometry
Body Weight
Technology

Keywords

  • cellular therapy
  • donor recruitment
  • donors

ASJC Scopus subject areas

  • Hematology

Cite this

Tasnády, S., Karászi, É., Szederjesi, A., Bihari, G., Juhász, Z., Hardi, A., ... Masszi, T. (Accepted/In press). Identification of the best-suited donor for generating virus-specific T cells. Vox sanguinis. https://doi.org/10.1111/vox.12857

Identification of the best-suited donor for generating virus-specific T cells. / Tasnády, Szabolcs; Karászi, Éva; Szederjesi, Attila; Bihari, György; Juhász, Zsófia; Hardi, Apor; Kriván, Gergely; Kállay, Krisztián; Reményi, Péter; Sinkó, János; Mikala, Gábor; Réti, Marienn; Masszi, Tamás.

In: Vox sanguinis, 01.01.2019.

Research output: Contribution to journalArticle

Tasnády, S, Karászi, É, Szederjesi, A, Bihari, G, Juhász, Z, Hardi, A, Kriván, G, Kállay, K, Reményi, P, Sinkó, J, Mikala, G, Réti, M & Masszi, T 2019, 'Identification of the best-suited donor for generating virus-specific T cells', Vox sanguinis. https://doi.org/10.1111/vox.12857
Tasnády S, Karászi É, Szederjesi A, Bihari G, Juhász Z, Hardi A et al. Identification of the best-suited donor for generating virus-specific T cells. Vox sanguinis. 2019 Jan 1. https://doi.org/10.1111/vox.12857
Tasnády, Szabolcs ; Karászi, Éva ; Szederjesi, Attila ; Bihari, György ; Juhász, Zsófia ; Hardi, Apor ; Kriván, Gergely ; Kállay, Krisztián ; Reményi, Péter ; Sinkó, János ; Mikala, Gábor ; Réti, Marienn ; Masszi, Tamás. / Identification of the best-suited donor for generating virus-specific T cells. In: Vox sanguinis. 2019.
@article{59217ff9475447ff8260501fcf669dab,
title = "Identification of the best-suited donor for generating virus-specific T cells",
abstract = "Background and objectives: Administration of virus-specific T cells (VSTs) is a viable antiviral treatment strategy after allogeneic HSCT, even if conventional therapies fail. Third-party donors are often chosen for the generation of the VST product. The eligibility of the donor has to be tested in a rigorous donor screening procedure, since the isolation technology only targets pre-existing VSTs. Materials and methods: In a period of 3 years, we performed 32 VST treatments for 28 patients. Targeting four different viruses, 284 healthy individuals underwent 417 donor screening procedures. VSTs were counted by flow cytometry detecting interferon-gamma (IFN-γ) producing T cells. Generation of the VSTs was performed from leukapheresis products in a fully automated and closed system using magnetic cell separation. Results: The mean circulating VST frequencies ranged from 0·006{\%} to 0·328{\%}. The average yield of viable VSTs in the product was 1·83·106 cells, while the average VST dose calculated for the patient's body weight was 4·63·104/kg. The mean purity – percentage of VSTs within the T cells – of all T-cell products was 62·9{\%}. Correlation was identified between the frequency of the VSTs in the peripheral blood of the donor and the VST numbers of the end product; the strongest correlation was seen for CMV. Conclusion: This paper focuses on the T-cell donors, highlighting some key points on the donor selection process. Based on the findings in connection with the CMV therapies, peripheral VST seems to be the best predictor of the VST content of the final product administered to the patient.",
keywords = "cellular therapy, donor recruitment, donors",
author = "Szabolcs Tasn{\'a}dy and {\'E}va Kar{\'a}szi and Attila Szederjesi and Gy{\"o}rgy Bihari and Zs{\'o}fia Juh{\'a}sz and Apor Hardi and Gergely Kriv{\'a}n and Kriszti{\'a}n K{\'a}llay and P{\'e}ter Rem{\'e}nyi and J{\'a}nos Sink{\'o} and G{\'a}bor Mikala and Marienn R{\'e}ti and Tam{\'a}s Masszi",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/vox.12857",
language = "English",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Identification of the best-suited donor for generating virus-specific T cells

AU - Tasnády, Szabolcs

AU - Karászi, Éva

AU - Szederjesi, Attila

AU - Bihari, György

AU - Juhász, Zsófia

AU - Hardi, Apor

AU - Kriván, Gergely

AU - Kállay, Krisztián

AU - Reményi, Péter

AU - Sinkó, János

AU - Mikala, Gábor

AU - Réti, Marienn

AU - Masszi, Tamás

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and objectives: Administration of virus-specific T cells (VSTs) is a viable antiviral treatment strategy after allogeneic HSCT, even if conventional therapies fail. Third-party donors are often chosen for the generation of the VST product. The eligibility of the donor has to be tested in a rigorous donor screening procedure, since the isolation technology only targets pre-existing VSTs. Materials and methods: In a period of 3 years, we performed 32 VST treatments for 28 patients. Targeting four different viruses, 284 healthy individuals underwent 417 donor screening procedures. VSTs were counted by flow cytometry detecting interferon-gamma (IFN-γ) producing T cells. Generation of the VSTs was performed from leukapheresis products in a fully automated and closed system using magnetic cell separation. Results: The mean circulating VST frequencies ranged from 0·006% to 0·328%. The average yield of viable VSTs in the product was 1·83·106 cells, while the average VST dose calculated for the patient's body weight was 4·63·104/kg. The mean purity – percentage of VSTs within the T cells – of all T-cell products was 62·9%. Correlation was identified between the frequency of the VSTs in the peripheral blood of the donor and the VST numbers of the end product; the strongest correlation was seen for CMV. Conclusion: This paper focuses on the T-cell donors, highlighting some key points on the donor selection process. Based on the findings in connection with the CMV therapies, peripheral VST seems to be the best predictor of the VST content of the final product administered to the patient.

AB - Background and objectives: Administration of virus-specific T cells (VSTs) is a viable antiviral treatment strategy after allogeneic HSCT, even if conventional therapies fail. Third-party donors are often chosen for the generation of the VST product. The eligibility of the donor has to be tested in a rigorous donor screening procedure, since the isolation technology only targets pre-existing VSTs. Materials and methods: In a period of 3 years, we performed 32 VST treatments for 28 patients. Targeting four different viruses, 284 healthy individuals underwent 417 donor screening procedures. VSTs were counted by flow cytometry detecting interferon-gamma (IFN-γ) producing T cells. Generation of the VSTs was performed from leukapheresis products in a fully automated and closed system using magnetic cell separation. Results: The mean circulating VST frequencies ranged from 0·006% to 0·328%. The average yield of viable VSTs in the product was 1·83·106 cells, while the average VST dose calculated for the patient's body weight was 4·63·104/kg. The mean purity – percentage of VSTs within the T cells – of all T-cell products was 62·9%. Correlation was identified between the frequency of the VSTs in the peripheral blood of the donor and the VST numbers of the end product; the strongest correlation was seen for CMV. Conclusion: This paper focuses on the T-cell donors, highlighting some key points on the donor selection process. Based on the findings in connection with the CMV therapies, peripheral VST seems to be the best predictor of the VST content of the final product administered to the patient.

KW - cellular therapy

KW - donor recruitment

KW - donors

UR - http://www.scopus.com/inward/record.url?scp=85074798647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074798647&partnerID=8YFLogxK

U2 - 10.1111/vox.12857

DO - 10.1111/vox.12857

M3 - Article

C2 - 31667887

AN - SCOPUS:85074798647

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

ER -